A case of salvage surgery following chemoradiotherapy and durvalumab for initially unresectable superior sulcus tumor with N3 involvement

Takehiko Manabe; Masatoshi Kanayama; Hiroki Matsumiya; Katsuma Yoshimatsu; Masataka Mori; Natsumasa Nishizawa; Akihiro Taira; Masaru Takenaka; Koji Kuroda; Koichi Azuma; Fumihiro Tanaka

doi:10.1186/s44215-024-00169-z

A case of salvage surgery following chemoradiotherapy and durvalumab for initially unresectable superior sulcus tumor with N3 involvement

Gen Thorac Cardiovasc Surg Cases. 2024 Oct 1;3(1):44. doi: 10.1186/s44215-024-00169-z.

Affiliations

¹ Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan. t-manabe-ts@med.uoeh-u.ac.jp.
² Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
³ Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.

Abstract

Background: Durvalumab after chemoradiation (PACIFIC regimen) provides favorable treatment outcomes for unresectable stage III non-small cell lung cancer (NSCLC). The feasibility of salvage surgery after the PACIFIC regimen has been reported in some studies; however, its efficacy remains unclear. We herein present the first case of salvage surgery after the PACIFIC regimen for a superior sulcus tumor with N3 involvement, in which a pathological complete response was achieved.

Case presentation: A 53-year-old man with a left superior sulcus tumor with N3 (# 1L, #4R) involvement (adenocarcinoma, clinical T3N3M0/IIIC) underwent concurrent chemoradiotherapy (2 cycles of cisplatin plus vinorelbine with 60 Gy radiotherapy) followed by durvalumab treatment for 1 year at a previous hospital. The PACIFIC regimen provided a significant primary tumor shrinkage (diameter 3.1 cm to 0.5 cm) with the disappearance of 18F-fluorodeoxyglucose uptake in all nodes. Six months after the end of the PACIFIC regimen, only the primary tumor showed enlargement (diameter 0.5 cm to 2.0 cm). Accordingly, local tumor recurrence was suspected. Salvage surgery (left upper lobectomy with combined chest wall resection [1st to 4th rib]) was performed. The histological examination revealed no viable tumor cells (ypT0N0M0). At 7 months after salvage surgery, the patient remains alive with no signs of tumor recurrence.

Conclusions: The present case suggests that salvage surgery may be feasible after the PACIFIC regimen for superior sulcus tumors. A long-term follow-up is essential to determine the efficacy of salvage surgery.

Keywords: Immune checkpoint inhibitor; Lung cancer; PACIFIC trial; Salvage surgery; Superior sulcus tumor.